Glioblastoma — frontier options in Massachusetts
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALNARECRUITING
Serial MRI Scans During Radiation Therapy
MRI IMAGING — 2 sites
- TRIALPHASE1RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
M3554 — 11 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Program for GBM Subjects
RZ-001 — 1 site
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE2RECRUITING
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
Dose-escalated radiation therapy · Standard hypofractionated radiation — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 128 sites
- TRIALPHASE2RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib · Everolimus · Temozolomide (TMZ) — 20 sites
- TRIALEARLY_PHASE1RECRUITING
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
Troriluzole — 3 sites
- TRIALPHASE3RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Optune® device · Temozolomide · Pembrolizumab — 102 sites
- TRIALPHASE1RECRUITING
CARv3-TEAM-E T Cells in Glioblastoma
CARv3-TEAM-E T cells — 1 site
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 58 sites
- TRIALEARLY_PHASE1RECRUITING
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib · Lorlatinib with chemotherapy1 · Lorlatinib with chemotherapy 2 — 18 sites
- TRIALEARLY_PHASE1RECRUITING
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Larotrectinib · Larotrectinib surgical — 21 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE2RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
silevertinib in combination with temozolomide · temozolomide (TMZ) — 31 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500 · [68Ga]CM500 · PET/MR — 3 sites
- TRIALPHASE1RECRUITING
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
rHSC-DIPGVax · Balstilimab · Zalifrelimab — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 63 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE2RECRUITING
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
5-ALA HCl + LIDU SDT · Placebo + Sham SDT — 11 sites
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 61 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
DCVax-L — 27 sites
- TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NEO212 Oral Capsule · Ipilimumab · Pembrolizumab — 8 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALPHASE2RECRUITING
G-CSF After Chemo-radiation in Patients With Glioblastoma
Granulocyte Colony Stimulating Factor (G-CSF) · Radiation Therapy + Temozolomide — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE2RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Temozolomide · Neratinib · QBS10072S — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALEARLY_PHASE1RECRUITING
Implantable Microdevice In Primary Brain Tumors
Microdevice — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.